Endovalve, Inc.

Endovalve is a spinout of the University of Pennsylvania School of Medicine that is developing a percutaneous mitral valve replacement system to treat mitral regurgitation, an increasingly common heart disease. Some 25,000 mitral valve replacements and about 13,000 mitral valve repairs are annually performed in the United States alone, but only the severest cases are treated today because of the risks of open-heart surgery. The Endovalve system is designed to allow for a complete mitral valve replacement without open-heart surgery so that many more sufferers will not have to defer treatment until the disease becomes critical or a serious cardiac event takes place. Battelle Ventures and its affiliate fund, Innovation Valley Partners, were the sole investors in the company's series A financing. Battelle Ventures General Partner Tracy Warren serves on the Board of Directors.

The Endovalve device is in the early stages of design development and has not been approved for clinical use nor has an Investigational Device Exemption (IDE) been filed. No clinical studies have yet been planned or initiated. (See deal announcement).

Company Web Site
www.endovalve.com